Anjiolab Completes Phase 2a Clinical Trial for Non-Alcoholic Steatohepatitis Treatment

[Asia Economy Reporter Kwon Jaehee] Anjiolab announced on the 17th that the Phase 2a clinical trial of AL101-NASH, a treatment for non-alcoholic steatohepatitis (NASH), has been completed.

The company stated, "Based on the clinical results, ALS-L1023 is considered a drug that can be safely used in patients with non-alcoholic steatohepatitis," and added, "We plan to present the results of this clinical trial in papers and academic conferences, and also intend to pursue technology transfer."